Ligand Pharmaceuticals Incorporated (LGND) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ligand Pharmaceuticals Incorporated (LGND) has a cash flow conversion efficiency ratio of 0.049x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($48.69 Million) by net assets ($997.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LGND net asset quality index to measure how much of total assets are equity-financed.
Ligand Pharmaceuticals Incorporated - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how Ligand Pharmaceuticals Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Ligand Pharmaceuticals Incorporated to evaluate the quality of earnings relative to operating cash generation.
Ligand Pharmaceuticals Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ligand Pharmaceuticals Incorporated ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Atlanta Braves Holdings, Inc. Series C Common Stock
NASDAQ:BATRK
|
0.042x |
|
TAG Immobilien AG
F:TEG
|
0.040x |
|
Sprott Inc.
TO:SII
|
0.144x |
|
Viscofan
MC:VIS
|
0.066x |
|
Wanda Cinema Line Corp
SHE:002739
|
0.061x |
|
Cargotec Oyj
HE:CGCBV
|
0.087x |
|
Regional S.A.B. de C.V
MX:RA
|
-0.056x |
|
Henan Yuneng Holdings Co Ltd
SHE:001896
|
0.427x |
Annual Cash Flow Conversion Efficiency for Ligand Pharmaceuticals Incorporated (1994–2025)
The table below shows the annual cash flow conversion efficiency of Ligand Pharmaceuticals Incorporated from 1994 to 2025. For the full company profile with market capitalisation and key ratios, see Ligand Pharmaceuticals Incorporated stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.02 Billion | $49.36 Million | 0.049x | -58.48% |
| 2024-12-31 | $830.44 Million | $97.05 Million | 0.117x | +65.22% |
| 2023-12-31 | $700.91 Million | $49.58 Million | 0.071x | -69.34% |
| 2022-12-31 | $597.49 Million | $137.85 Million | 0.231x | +140.43% |
| 2021-12-31 | $821.16 Million | $78.80 Million | 0.096x | +24.73% |
| 2020-12-31 | $709.52 Million | $54.59 Million | 0.077x | +301.21% |
| 2019-12-31 | $767.23 Million | $-29.34 Million | -0.038x | -111.05% |
| 2018-12-31 | $560.91 Million | $194.06 Million | 0.346x | +54.80% |
| 2017-12-31 | $418.65 Million | $93.57 Million | 0.224x | +31.56% |
| 2016-12-31 | $370.85 Million | $63.00 Million | 0.170x | +23.93% |
| 2015-12-31 | $304.39 Million | $41.73 Million | 0.137x | -83.73% |
| 2014-12-31 | $24.41 Million | $20.57 Million | 0.843x | +102.05% |
| 2013-12-31 | $49.61 Million | $20.69 Million | 0.417x | +6760.24% |
| 2012-12-31 | $26.48 Million | $161.00K | 0.006x | +104.48% |
| 2011-12-31 | $8.65 Million | $-1.17 Million | -0.136x | -103.50% |
| 2010-12-31 | $-6.99 Million | $-27.07 Million | 3.872x | +142.89% |
| 2009-12-31 | $3.74 Million | $-33.80 Million | -9.028x | -553.70% |
| 2008-12-31 | $-10.37 Million | $-20.62 Million | 1.990x | +159.28% |
| 2007-12-31 | $29.11 Million | $-97.73 Million | -3.357x | +33.72% |
| 2006-12-31 | $27.35 Million | $-138.52 Million | -5.064x | -6585.05% |
| 2005-12-31 | $-110.42 Million | $8.37 Million | -0.076x | +0.84% |
| 2004-12-31 | $-75.32 Million | $5.75 Million | -0.076x | -2072.05% |
| 2003-12-31 | $70.73 Million | $274.00K | 0.004x | +101.14% |
| 2002-12-31 | $74.02 Million | $-25.11 Million | -0.339x | -198.64% |
| 2001-12-31 | $-57.88 Million | $-19.91 Million | 0.344x | -59.96% |
| 2000-12-31 | $-55.12 Million | $-47.35 Million | 0.859x | -63.65% |
| 1999-12-31 | $-25.60 Million | $-60.50 Million | 2.363x | -59.55% |
| 1998-12-31 | $-11.40 Million | $-66.60 Million | 5.842x | +1595.40% |
| 1997-12-31 | $34.30 Million | $-13.40 Million | -0.391x | +59.53% |
| 1996-12-31 | $34.50 Million | $-33.30 Million | -0.965x | +28.44% |
| 1995-12-31 | $28.10 Million | $-37.90 Million | -1.349x | -148.06% |
| 1994-12-31 | $26.30 Million | $-14.30 Million | -0.544x | -- |
About Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help figh… Read more